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Background. Whilevaccinationatbirth withMycobacterium bovisBacilliCalmette-Gu´ erin (BCG)protects againstseverechildhood
tuberculosis, there is no consensus as to which components of the BCG-induced immune response mediate this protection.
However, granulysin and perforin, found in the granules of cytotoxic T lymphocytes and Natural Killer (NK) cells, can kill
intracellularmycobacteria andare implicatedin protection againstMycobacterium tuberculosis. Methods.Wecomparedthecellular
expressionofgranulysinandperforin cytolytic molecules incord bloodandperipheral blood from10-week-old infantsvaccinated
at birth with either Japanese or Danish BCG, administered either intradermally or percutaneously. Results. In cord blood, only
CD56+ NK cells expressed granulysin and perforin constitutively. These cytolytic mediators were upregulated in CD4+ and CD8+
cord blood cells by ex vivo stimulation with BCG but not with PPD. Following BCG vaccination of neonates, both BCG and PPD
induced increased expression of granulysin and perforin by CD4+ and CD8+ T cells. There was no diﬀerence in expression of
cytolytic molecules according to vaccination route or strain. Conclusions. Constitutive expression of perforin and granulysin by
cord blood NK-cells likelyprovides innate immunity,while BCG vaccination-induced expression of these cytolytic mediators may
contribute towards protection of the neonate against tuberculosis.
1.Introduction
It is estimated that approximately one third of the world’s
population is infected with Mycobacterium tuberculosis
(M.tb) resulting in about 1.7 million deaths from tuber-
culosis (TB) annually [1]. Mycobacterium bovis Bacille
Calmette Gu´ erin (BCG) is the most commonly used vaccine
worldwide and the only vaccine available for the prevention
of TB. The vaccine oﬀers good protection against childhood
miliary disease and TB meningitis [2, 3] and has been
associated with a reduced risk of acute respiratory tract
infections in neonates [4]. However, BCG aﬀords very little
protection against pulmonary TB and other manifestations
of adult disease. It has been suggested that the strain of BCG
and the route of administration may aﬀect the eﬃcacy of the
vaccine [5–8] as well as determine the nature of the antigen-
speciﬁc T-cell responses [9].
Both innate and adaptive cellular immune responses
are required for an eﬀective host defense against M.tb and
individuals with defective cell-mediated immunity (CMI)2 Clinical and Developmental Immunology
have a predisposition towards developing TB, or towards
more severe disease [10]. T-cell derived interferon gamma
(IFN-γ) is widely recognized as important in antimicrobial
protection. This cytokine is essential for the activation of
macrophages, a process required to limit the replication
of the bacilli in these cells [11, 12]. However, despite
having a full repertoire of helper and cytotoxic T-cells, B-
cells, and dendritic cells (DC) [13], circulating neonatal
lymphocytes are functionally distinct as compared with
adults. Consequently, activation is submaximal [14]a n d
IFN-γ production in response to mycobacterial antigens
is signiﬁcantly lower in neonates [15, 16]. However, the
value of IFN-γ as the best correlate of protection against
TB has been challenged [17, 18]. Lymphoid cell-derived
cytotoxic molecules found in cytotoxic lymphocytes (CTL)
and natural killer (NK) cells have also been implicated in
contributing to protective immunity against intracellular
pathogens. These cells contain granules rich in granulysin,
perforin and granzyme, molecules that contribute to lysis
of infected cells. Granulysin, a member of the saponin-like
family of lipid binding proteins, has also been shown to
directly kill extracellular bacilli and, together with perforin,
was able to substantially reduce the viability of intracellular
M.tb [19].
The aim of our study was to evaluate the expression
of granulysin and perforin in NK cells and T-cells in cord
blood mononuclear cells (CBMCs) and to compare this with
peripheral blood mononuclear cells (PBMCs) from neonates
after vaccination with BCG. PBMCs from healthy adults
who were puriﬁed protein derivative of tuberculin (PPD)
responsive in vitro were used as controls. In addition, we
determined whether the route and strain ofBCG vaccination
aﬀected the expression of these cytolytic mediators. The
results show that while T-cells from CBMCs do not express
granulysin or perforin constitutively, BCG vaccination at
birth results in strong upregulation of these mediators in the
T-cells of 10-week-old infants. NK cells from CBMCs and
PBMC of vaccinated infants constitutively expressed both
markers. Variation in route and strain of BCG vaccine did
nothave a signiﬁcant eﬀecton cytotoxicmediatorexpression
in T-cells or NK cells of PBMC obtained from 10-week-old
neonates.
2.MaterialandMethods
2.1. Human Subjects and Vaccination. Healthy HIV-negative
pregnant women scheduled to undergo elective Ceasarian
section, due to previous Ceasarian sections, were recruited
for umbilical cord blood (UCB) collection. This population
was selected to avoid the eﬀects of labour on immune
responses.
Healthy 10-week-old infants were enrolled at primary
care clinics in the Cape Town region. At birth, the babies
had received either Japanese BCG (strain 172: Japan BCG
Laboratory) or Danish BCG (strain 1331: Statens Serum
Institute). The Japanese vaccine was administered either
intradermally (JID) or percutaneously (JPC), while the
Danish vaccine was given intradermally (DID). Infants with
any acute or chronic disease, born to an HIV+ mothers, or
living with a person with active tuberculosis, were excluded.
A positive ELISA test for HIV, performed on all infants, also
resulted in exclusion.
A positive proliferative response to PPD stimulation
in peripheral blood (as deﬁned by both microscopic cell
clustering and ﬂow cytometric evaluation) was used to
identify healthy adults with prior exposure to mycobacterial
antigens, and potentially latently infected with M.tb. All
volunteers were HIV negative and were clinically well.
Human participation was according to the US Department
of Health and Human Services and Good Clinical Practice
guidelines. This included the protocol approval by the
University of Cape Town Research Ethics Committee and
by the UMDNJ Institutional Review Board and informed
written consent from a parent of the neonate or from the
adult volunteers.
2.2. Cord Blood Mononuclear Cells (CBMCs). After inserting
a needle with collection tubing into the umbilical vein of
the placenta, the blood was allowed to ﬂow by gravity
into a standard blood donation bag (Sabax, Johannesburg,
South Africa) containing 2000 units of sodium heparin
(Sigma- Aldrich, Steinham, Germany). In the laboratory,
the UCB was diluted with equal volumes of Ca+ and
Mg+ free phosphate buﬀered saline (PBS, Bio Whittaker,
Walkersville,MD,USA),andmononuclearcellswereisolated
by density sedimentation using Ficoll-Hypaque (Sigma-
Aldrich, Steinham, Germany). Due to the large number of
erythroidprecursorcellsin UCB,theprocedurewasrepeated
[20]. After the ﬁnal wash the CBMCs were suspended in
RPMI (Bio Whittkaker) supplemented with 10% human AB
serum (Western Province Blood Transfusion Service, South
Africa).
2.3. BCG-Vaccinated Infant and PPD-Reactive Adult Periph-
eral Blood Mononuclear Cells (PBMCs). PBMC were sepa-
rated as described for CBMCs, except that a single density
gradient centrifugation was performed. PBMCs were cryop-
reserved until analysis: preliminary experiments showed no
signiﬁcant diﬀerence between cytolytic mediator expression
in freshly isolated PBMCs and cryopreserved PBMCs from
the same donors in both adults and 10-week-old infants
(data not shown). Cell viability was determined by trypan
blue exclusion dye (Sigma Aldrich).
2.4.StimulationofCBMCsandPBMCs. 1×106 cells/mlwere
stimulated with 6μg/ml of PPD (Statens Serum Institute,
DM) or 100 IU interleukin-2 (Aldesleukin, Chiron) for 7
days at 37◦Ci na5 %C O 2 humidiﬁed incubator. Unstim-
ulated cells served as a background control. The duration
of lymphoid cell stimulation was validated in preliminary
experiments where granulysin and perforin expression was
d e t e r m i n e de xv i v oa n d1 ,4 ,6 ,7 ,a n d8 / d a y sa f t e rP P Da n d
BCG stimulation. Although granulysin and perforin were
detected in NK cells ex vivo, little or no expression was seen
in CD4+ and CD8+ T-cells until 4 days after stimulation
and optimal expression peaked at day 7 (data not shown).Clinical and Developmental Immunology 3
CBMCs and PBMC isolated from adults who were PPD-
reactive were also stimulated with BCG (Danish BCG strain
1331, Statens Serum Institute) at a multiplicity of infection
(MOI) of 1:1 and 5:1, respectively, shown to be optimal in
preliminary experiments that evaluated cell death with the
viability stain 7AAD. The 7-day duration of lymphoid cell
stimulation was validated in preliminary experiments (data
not shown).
2.5. Flow Cytometric Analysis. After stimulation with appro-
priate stimuli, the cells were washed with PBS containing 1%
human AB serum and 0.1% sodium azide (Sigma Aldrich),
resuspended in the same medium (wash buﬀer)and counted
on a haemacytometer. Cell viability was determined by
trypan blue exclusion (Sigma Aldrich). Approximately 0.1
× 106 viable cells were stained with CD3 FITC (Caltag,
Burlingame, CA) or CD3 PerCP (BD Biosciences) and
either CD4 APC or CD8 APC (Caltag) or CD56 APC
(BD Biosciences) for 15 minutes at room temperature.
After washing, the cells were ﬁxed and permeabilised with
FACSPermeabilising Solution (BD Biosciences) then stained
with either rabbit polyclonal granulysin antibody (which
speciﬁcally recognises the 9 and 15-kDa forms of granulysin)
[21–23] at a concentration of 1/1000 or Perforin-FITC (BD
Biosciences) for 30 minutes at 4◦C. For granulysin staining,
F(ab)2 goat antirabbit IgG (H+L)-PE conjugated secondary
antibody (Caltag) was added for 30 minutes at 4◦C. The
cells were resuspended in the wash buﬀer for analysis on
a FACSCalibur using Cell Quest software. Isotypic matched
controls were used for all monoclonal antibodies while
normal rabbit serum (Sigma Aldrich) served as a control
for the granulysin polyclonal antibody. The ﬂow cytometric
gatingstrategy (shownin Figure 1(a))wasemployedin order
to deﬁne three distinct peripheral blood lymphocyte subsets
forquantiﬁcationofeithergranulysin orperforin expression.
The lymphocyte gate was deﬁned by forward and side scatter
cell characteristics (R1). Within this population, CD3+ T-
cells were split into CD3+4+ or CD3+8+ subsets (i.e., cells
that are in both gates R1 and R2), while NK cells were
operationallydeﬁnedasCD3−56+ (cellsthatareinbothgates
R1 and R3) (Figure 1).
2.6. Statistical Analysis. The primary outcomes were expres-
sion of granulysin or perforin in CD4+ or CD8+ T-
cells, or NK cells. These outcomes were compared according
to mycobacterial infection status (na¨ ıve cord blood, BCG-
vaccinated infants, and healthy PPD-reactive adults) and
according to antigen used in assays. The Mann-Whitney
two-tailed test or Kruskal Wallis test was used to determine
signiﬁcance of diﬀerences, and results are stated throughout
the text as medians with interquartile range. All statistical
analysiswascarriedoutusingeitherGraphPadInstat (version
3.06) or GraphPad Prism software (version 4.0).
3.Results
3.1. Participants. Ten pregnant volunteers with a mean age
of 26 years (range 19–34) consented to donating cord blood.
Ten PPD-reactive healthy adults (PPD+) with a mean age
of 36 years (range 24–55) were enrolled in the study. The
volunteers comprised of 5 males and 5 females. Forty ﬁve
babies, vaccinated at birth with BCG, were enrolled in
this study: 15 babies received DID whilst 31 babies were
vaccinated with Japanese BCG: 15 with JID and 16 with JPC.
3.2. Eﬀect of BCG Vaccination on PPD-Induced Granulysin
Expression. CBMCs isolated from placental umbilical veins
of 10 neonates were stimulated with PPD for 7 days. CD4+
and CD8+ T-cells and CD56+ NK cells were analysed by
ﬂow cytometry for granulysin expression. IL-2 stimulated
CBMCs acted as a positive control. Unstimulated and PPD
stimulated cord blood CD4+ T-cells were either negative or
expressed very low levels of granulysin (Figure 2(a)). Similar
results were seen in cord blood CD8+ T-cells (Figure 2(b)).
IL-2 stimulation of CBMCs in vitro induced an increase
i nt h ep e r c e n t a g eo fg r a n u l y s i np o s i t i v eC D 4 + T cells of
23.5% (12.5–62, P = .0001) and CD8+ T cells of 32.5%
(10.5–55.5, P = .0001). In contrast to T-cells, unstimu-
lated NK cells expressed high levels of granulysin and the
percentage of positive cells was decreased following PPD
stimulation although this was not statistically signiﬁcant (P
= .09, Figure 2(c)). Similarly, the level of granulysin in IL-
2s t i m u l a t e dC D 5 6 + cells was lower at 20.5% (11.8–32.5),
compared to the unstimulated cells at 52% (34.7–59.8), and
this was statistically signiﬁcant (P = .0025, not shown).
When infants were vaccinated with BCG at birth and
their PBMC evaluated for granulysin expression at 10 weeks
postvaccination, a diﬀerent pattern was seen. Granulysin
was expressed in 2% (0.5–3.5) of unstimulated CD4+ and
1% (1–2.5) of unstimulated CD8+ T-cells (Figures 2(a)
and 2(b)). After 7 days of in vitro PPD stimulation of
PBMC, granulysin expression in both CD4+ and CD8+ T-
cells increased signiﬁcantly to a median of 61% (46–76, P
≤ .0001) and 53% (9–72, P ≤ .0001) of cells, respectively.
IL-2 stimulation of PBMC induced similar strong expression
with median of 34% (16.5–81, P ≤ .0001) for CD4+ T cells
and 69% (27.5–87, P ≤ .0001) for CD8+Tc e l l( n o ts h o w n ) .
Thus, in contrast to CBMCs, PBMC of vaccinated babies
had signiﬁcantly higher levels of granulysin expressing T
lymphocytes after in vitro PPD stimulation. This high level
of expression is comparable to that previously obtained in
adults [23]. Similar to CBMCs, constitutive expression of
granulysin was seen in unstimulated NK cells of PBMC from
vaccinated infants.
Healthy PPD+ adult volunteer controls were also evalu-
ated for granulysin expression in NK+ cells, and CD4+ and
CD8+ T cells. Unlike both the CBMCs and PBMC from
the 10-week-old infants, constitutive granulysin expression
was seen in 8% (5.5–22.5) of CD8+ T-cells (Figure 2).
The median granulysin expression in PPD-stimulated adult
PBMC was 39.5% (18–47.3) and 40.5% (28–48) for CD4+
and CD8+ T cells, respectively, and 57% (41.8–65.5) for NK
cells. Compared to unstimulated cells, granulysin expres-
sion was signiﬁcantly increased in PPD-stimulated CD4+
(P< .0001) and CD8+ (P = .0015) T-cells but there was
no signiﬁcant diﬀerence in granulysin expression between4 Clinical and Developmental Immunology
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Figure 1: (a) Flow cytometric diagram illustrating the gating strategy for the expression of granulysin (or Perforin) in T-cells and NK cells.
R1 represents a general lymphocyte gate including all lymphocytes in a PPD stimulated PBMC sample. R2 incorporates all CD3+ T-cells
within the R1 gate, and R3 includes all cells that are CD3−. Percentage cells expressing granulysin (represented on the y-axis) are evaluated
by dividing the number of cells in A by the number of cells in A + B × 100. (b) Flow cytometric dotplots of granulysin in unstimulated or
PPD-stimulated representative samples of cord blood mononuclear cells in the left column, 10-week-old infants after BCG vaccination in
the middle column, and PBMC from healthy PPD+ adult volunteers in the right column. Results shown represent T-lymphocytes which are
CD4+/CD3+ or CD8+/CD3+ or NK cells which are CD56+/CD3−.S e eSection 2 for details.
unstimulated and PPD-stimulated NK cells (P = .8). How-
ever, similar to CBMCs and PBMC from vaccinated babies,
constitutive granulysin expression was also seen in 54.5%
(34.8–73) of unstimulated CD56+ cells from healthy PPD+
adult controls.
3.3. Eﬀect of BCG Vaccination on PPD-Induced Perforin
Expression. A similar analysis was undertaken to determine
levels of expression of perforin. Neither unstimulated CD4+
nor CD8+ T-cells from cord blood, nor unstimulated
CD4+ or CD8+ T cells from 10-week-old vaccinated infantsClinical and Developmental Immunology 5
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Figure 2: Granulysin expression in CD4+ (a) and CD8+ (b) T-cells and CD56+ (c) NK cells in unstimulated (US) and PPD-stimulated
mononuclear cells isolated from cord blood (CB, n = 10) or peripheral blood from BCG-vaccinated infants (10w, n = 45) or healthy PPD+
adult volunteers (ND, n = 10). Signiﬁcanceis shown as PPD stimulationin CB compared to 10-week-old infants and healthy adult controls,
and 10-week-old infants compared to healthy adult controls. The box extends from the 25th to 75th percentile, the line represents the
median, and the whiskers represent the maximum and minimum values.
expressed perforin (Figures 3(a) and 3(b)). In contrast, 38%
(17–61.8)ofNK-cellsinCBMCsand6%(0–48.3)ofNKcells
in 10-week-old infant PBMC constitutively expressed the
cytolytic marker (Figure 3(c)). Again, PPD stimulation did
not induce expression of perforin in CD4+ or CD8+ T-cells
from cord blood (Figures 3(a) and 3(b)) while a reduction in
the levels of expression in CD56+ NK cells to 16.5% (8–33.2,
P = .02) as compared to unstimulated CBMCs was noted.
In contrast, PPD stimulation induced signiﬁcantly increased
expression of perforin in PBMC of vaccinated infants both
in CD4+ T-cells (P = .04) and CD8+ T-cells (P = .009) (27%
(13.8–44.3) and 38.5% (19.5–52.8), resp.) as well as in NK
cells (P< .0001) (87.5% (66–95)). Compared to CBMCs,
there was a signiﬁcant diﬀerence in perforin expression after
PPD stimulation in the 10-week-old vaccinated infants in
CD4and CD8T-cells (P,0.0001forbothT-cells, Figures2(a)
and 2(b)) and in NKcells (P = .0003, Figure 3(c)). After IL-2
stimulation, 18% (14–28.5, P = .0015) of CD4+ T-cells and
36% (22–40, P = .002) of CD8+ T-cells expressed perforin
(not shown).
In PPD+ adults, constitutive expression of perforin was
seen in 3.5% (2–11.8) of CD8+ T-cells and 76.5% (57.5–
85.8) of NK cells; after PPD stimulation, 14.5% (8.8–16.8)of
CD4+ T-cells and 21% (17.3–25.3)ofCD8+ T-cells expressed
perforin. PPD stimulation ofNK cellsresulted in a reduction
of perforin expression (from 76.5% to 60%).
3.4. Eﬀect of BCG Stimulation on Granulysin and Perforin
Expression in CD4+ and CD8+ T Cells of CBMCs and in
PBMC of PPD+ Healthy Adults. PBMC from healthy PPD+
adults and CBMCs were stimulated with Danish BCG, and
granulysin and perforin expression was determined within6 Clinical and Developmental Immunology
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Figure 3: Perforin expression in CD4+ (a) and CD8+ (b) T-cells and CD56+ (c) NK cells in unstimulated (US) and PPD-stimulated
mononuclear cells isolated from cord blood (CB, n = 10) or peripheral blood from BCG-vaccinated infants (10w, n = 45) or healthy PPD+
adult volunteers (ND, n = 10). Signiﬁcanceis shown as PPD stimulationin CB compared to 10-week-old infants and healthy adult controls,
and 10-week-old compared to healthy adult controls. The box extends from the 25th to 75th percentile, the line represents the median, and
the whiskers represent the maximum and minimum values.
the respective CD3+ cells. Unlike PPD, BCG stimulation
d i dr e s u l ti na ni n c r e a s ei nb o t hg r a n u l y s i na n dp e r f o r i n
expressions in CBMCs. There was a statistically signiﬁcant
diﬀerence in granulysin expression in BCG-stimulated T-
cells compared to PPD-stimulated T-cells (P ≤ 0.0001 for
CD4+ and P = .0005 for CD8+,F i g u r e s4(a) and 4(c))
in CBMCs. Similarly, perforin-expressing T-cells were also
increased in BCG-stimulated compared to PPD-stimulated
CBMCs (P = .003 for CD4+ and P = .004 for CD8+,
Figures 4(b) and 4(d)). 10.5% (4–25) of CD4+ T-cells and
11% (6–27) of CD8+ T-cells expressed granulysin after BCG
stimulation (Figure 4), and perforin expression was seen in
5.5% (2.5–17) and 8% (3.8–19) of CD4+ and CD8+ T-
cells, respectively, after BCG stimulation. Thus, although
the percentage of expression was considerably lower than
in healthy PPD positive adults, signiﬁcant expression was
induced in both lymphocyte subsets compared to PPD stim-
ulation. In contrast, in PPD+ healthy adult T-cells, equally
strong granulysin and perforin expression was obtained with
no signiﬁcant diﬀerence between PPD and BCG stimulation
being noted (Figures 4(a)–4(d)).
3.5. Eﬀect of Route and Strain of the BCG Vaccine on Gran-
ulysinand PerforininT-Cells and NKCells ofPBMCsfrom 10-
Week-Old Infants. To evaluate whether the strain of BCG or
the route of administration of the vaccine aﬀected the extent
of cytotoxic molecule expression, PBMC from 10-week-old
infants vaccinated with either Danish BCG administered
intradermally (n = 14 granulysin and n = 3 for perforin) or
Japanese BCG administered either intradermally (n = 15 for
granulysin and n = 4 for perforin) or percutaneously (n =
16 granulysin, and n = 7 for perforin) were evaluated for
granulysin and perforin expression. Although the number
of patients evaluated for perforin expression was low, no
signiﬁcant diﬀerences were found in granulysin or perforin
expression between vaccination with Japanese or DanishClinical and Developmental Immunology 7
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Figure4:PercentageCD4+3+,CD8 +3+ expressingGranulysin(a,c),orPerforin(b,d)inunstimulated(US)orPPD-orBCG-stimulatedcord
bloodmononuclearcells (CBn = 10)orperipheralbloodmononuclearcells from healthyPPD+ adult volunteers (ND n = 10).Signiﬁcanceis
shown between PPD and BCG stimulation in CB and adult volunteers. The box extends from the 25th to 75th percentile, the line represents
the median, and the whiskers represent the maximum and minimum values.
BCG. Similarly, the route of administration of the vaccine
also did not have any eﬀect on expression of these markers
(data not shown).
4.Discussion
In the current study, we have evaluated expression of
the cytolytic mediators perforin and granulysin in both
CD56+ NK cells and in CD4+ and CD8+ T-cell subsets
in CBMCs and observed that (i) intrinsic expression of
cytolyticmediatorswaslimitedtoCD56+ cellsandnotfound
in CD4+ and CD8+ T-cells and (ii) induction of perforin
and granulysin expression in cord blood T-cells occurred
selectively in response to in vitro stimulation with BCG,
but not PPD. In contrast, in 10-week-old BCG-vaccinated
infants, upregulation of perforin and granulysin expression
in CD4+ and CD8+ T-cell was demonstrable in response
to both BCG and PPD stimulation (data not shown). In
this study, the response was independent of variation in
vaccine strain or route of vaccine delivery (data not shown),
although the sample size was small and not statistically
powered. To our knowledge, a comprehensive comparative
evaluation of NK and CD4+ and CD8+ T subset cytolytic
mediator expression in cord blood and in BCG vaccinated
infants has not been documented before. Previous studies
have reported that cord blood CD4+ lymphocytes lack
constitutive expression of perforin [24]w h i l em o s tC D 8 + T-
cells of newborns have been shown to contain perforin and
granzyme. In contrast, we observed that unstimulated cord
blood CD8+ T-cells did not express granulysin or perforin.
This diﬀerence may be explained by the fact that in our8 Clinical and Developmental Immunology
study the CBMCs were from mothers undergoing caesarean
section. During normal vaginal delivery, cytokines including
IL-15 may be induced which could activate CD8+ T cells to
acquire cytotoxic potential [25].
Considerable evidence supports the observation that
cytotoxic T-cell activation occurs during induction of the
host protective immune response to TB [26–28]. We have
previously documented CD4+ cytotoxic activity in BCG-
vaccinated neonates using a chromium release assay [29].
It has previously been shown that the level of expression of
cytotoxic mediators is directly related to functional cytotoxic
activity of memory CD8+ T-cells [30]. Using this approach,
we have reported on CD8+ cytotoxic molecule expression
in infants who had received BCG vaccination at birth
[31]. Here we demonstrate that cytotoxic cells expressing
granulysinandperforinconstitutivelyexistinneonatalblood
even before BCG vaccination. Perforin and granulysin are
important cytolytic eﬀector molecules involved in lysis of
infected macrophages. Granulysin, found in the granules
of cytotoxic T-lymphocytes and NK cells, has a broad
spectrum of antimicrobial activity [19]. The molecule has
been shown to kill extracellular M. tuberculosis and, together
with perforin, is bactericidal to intracellular organisms
[19]. In addition, granulysin and perforin were signiﬁcantly
increased in lymphoid cells of cattle following vaccination
with M. bovis BCG and M. bovis ΔRD1 compared with
nonvaccinated animals [32].
IFN-γ production by CBMC NK cells is most needed
after birth [33, 34], at a time when CD4+ CD45RO- T-
cells have down-regulated Th1 function by transcriptional
regulation of the IFN-γ promoter gene due to hyper-
methylation [35]. Intrinsic cytolytic mediator expression
provides a second mechanism for NK cell mediated pro-
tective immunity during this critical period of heightened
susceptibility to mycobacterial infection. Our observation
that BCG upregulates cytotoxic molecules in cord blood
CD4+ and CD8+ T-cells may also be secondary to activation
of cells of the innate immune system. Since IL-2 treatment
of the T-cells of cord blood directly upregulated perforin
and granulysin expression, the eﬀect of BCG could be via
activation of NK cells to produce IL-2 which in turn could
aﬀectCD4+ andCD8+ T-cellactivation.Supportforacentral
role ofNKcellsin the host response against TB infection also
comes from the bovine model where activated NK cells were
shown to have increased granulysin and perforin expression
and to lyse Mycobacterium bovis BCG-infected alveolar and
monocyte-derived macrophages [36].
The role of IFN-γ producing CD4+ T-cells in protection
against TB is well described [37–39]. Support for a role for
cytotoxic CD4+ eﬀectors in protective immunity against TB
comes from studies carried out in BCG-vaccinated cattle. In
the bovine model, memory CD4+ T-cells expressing elevated
levelsofperforin andgranulysin strongly lysedBCG-infected
macrophages [40]. Cytotoxic CD4+ T-cells have also been
shown to use granulysin to kill Cryptococcus neoformans
[41]. Furthermore, cytotoxicgranulysin-expressing CD4+ T-
cells have been isolated from skin lesions of tuberculoid lep-
rosy patients [42]. Recently, Murray et al. showed that BCG
vaccination induced speciﬁc CD8+ T-cells which produced
IFN-γ and had increased expression of cytotoxic proteins in
response to BCG stimulation in vitro, providing evidence of
a role for CD8+ T-cells as well [31]. This is supported by the
ﬁnding of reduced perforin and granulysin coexpression in
CD8+ T-cellsfoundatthesiteofinfectioninchronicTB[43].
In the present study, we observed that there was no
statistical diﬀerence in granulysin or perforin expression
in cells obtained from neonates vaccinated at birth with
either JID or DID and no diﬀerence between vaccinations
via the two routes (intradermal versus percutaneous) of
administration of the Japanese BCG. Diﬀerences have been
reported in a study using a similar but larger cohort of
infants, where JPC induced signiﬁcantly more BCG-speciﬁc
IFN-γ producing CD4+ and CD8+ T-cells and greater Th1-
speciﬁc immunity than JID or DID [9]. In addition, JPC
induced greater CD4+ and CD8+ T-cell proliferation. Taken
together, the data suggest that distinct factors are involved
in promoting the development of the two pathways, that
is, Th1 cytokine and T-cell proliferation and expansion of
cytotoxiccellsexpressing granulysinandperforin. Insupport
of this dichotomy, it has been shown that BCG-infected
immature DCs selectively expanded perforin-positive CD8+
T-cells with little contribution from cytokines, including
IFN-γ,T N F - α,o rI L - 1 2[ 44]. In contrast, IL-15 promotes
granulysin expression [36, 45] while IL-21 has been shown
to enhance lytic activity of cytotoxic T-cells and NK cells
[46].These ﬁndings may have implications for immunother-
apeutic boosting of cytotoxic CD8+ activity in TB and BCG
vaccination protocols. In addition to therapeutic strategies
aimed at inhibition of IL-4 and TGFβ [47], molecular
engineering of BCG to incorporate IL-15 or IL-21 could
result in enhanced cytotoxic activity of both NK cells and
CD8+ cytotoxic T-cells.
In conclusion, data presented here demonstrate (i)
constitutive expression of granulysin and perforin cytolytic
mediators in NK cells which could provide innate protective
immunity for newborn infants and (ii)that BCG vaccination
at birth can induce a cytolytic eﬀector function in neonates,
where CD4+ and CD8+ T-cells are all essentially na¨ ıve.
By contrast, PPD antigenic stimulation could only induce
cytolytic eﬀector functions in memory CD4+ and CD8+
T-cells. While no currently available immunologic test can
predict vaccine eﬃcacy, BCG readily elicits a type 1 cytokine
response [29, 48] and it has been proposed that additional
factors may be important for vaccine eﬃcacy. These include
IL-4 and the Th1 cytokine balance [49, 50] and induction
of cytolytic activity in memory T-cells [40, 51]. Further
research is needed to establish if BCG-induced cytolytic
mediator expression issustained inmemory CTL.It has been
postulated that protection due to BCG vaccination wanes
with time [52] which may be due to overattenuation of
BCG strains with resultant gene deletions [53]a n df a i l u r et o
stimulate a durable immune response.
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